Switch from Boosted PI to Dolutegravir **NEAT 022**



Switching from a Boosted PI to Dolutegravir NEAT 022: Design

Study Design

 Background: Randomized, open-label, multicenter trial in Europe evaluating the impact of switching from a boosted PI to dolutegravir in virologically suppressed persons with older age or elevated cardiovascular risk.

Inclusion Criteria

- Age ≥50 years or Framingham 10-year estimated cardiovascular event risk >10%
- HIV RNA <50 copies/mL
- On 2 NRTI's + boosted PI
- No prior virologic failure and no genotypic resistance mutations

Switch Regimen Dolutegravir + 2 NRTI's (n = 205)Maintenance Regimen **Boosted PI + 2 NRTI's** (n = 210)48 weeks (primary endpoint), after which

all participants switch to DTG + 2 NRTI's





Switching from a Boosted PI to Dolutegravir NEAT 022: Baseline Regimens


Baseline Regimens in NEAT 022 Study DTG + 2 NRTI's PI/r + 2 NRTI's(n = 210)(n = 205)**NRTI Backbone** Tenofovir DF-Lamivudine 134 (65.4%) 135 (64.3%) Abacavir-Lamivudine 63 (30.7%) 67 (31.9%) 8 (3.9%) 8 (3.8%) Other **Boosted PI** 105 (51.5%) 107 (51.0%) Darunavir + ritonavir 74 (35.2%) Atazanavir + ritonavir 77 (37.7%) Other 22 (10.7%) 29 (13.8%)

Source: Gatell JM, et al. AIDS. 2017;31:2503-14.



Switching from a Boosted PI to Dolutegravir NEAT 022: Results


Week 48: Virologic Response by FDA Snapshot Analysis (ITT)





Switching from a Boosted PI to Dolutegravir NEAT 022: Results

Mean Percentage Change in Lipids at 48 Weeks





Switching from a Boosted PI to Dolutegravir NEAT 022: Conclusion

Interpretation: "Switching to a dolutegravir regimen in virologically suppressed HIV type 1 patients with high cardiovascular disease risk was noninferior, and significantly improved lipid profiles."

Source: Gatell JM, et al. AIDS. 2017;31:2503-14.



Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.



